| Literature DB >> 29545647 |
Yi-Lin Zhang1, Peng-Xiao Chen1, Wei-Jie Guan2,3, Hong-Mei Guo1,4, Zhuo-Er Qiu1, Jia-Wen Xu1, Yu-Li Luo1, Chong-Feng Lan1, Jian-Bang Xu1, Yuan Hao5, Ya-Xia Tan2, Ke-Nan Ye1, Zhao-Rong Lun1, Lei Zhao6, Yun-Xin Zhu1, Jiehong Huang1, Wing-Hung Ko5, Wei-De Zhong7, Wen-Liang Zhou8, Nan-Shan Zhong9.
Abstract
Airway epithelial cells harbor the capacity of active Cl- transepithelial transport and play critical roles in modulating innate immunity. However, whether intracellular Cl- accumulation contributes to relentless airway inflammation remains largely unclear. This study showed that, in airway epithelial cells, intracellular Cl- concentration ([Cl-]i) was increased after Pseudomonas aeruginosa lipopolysaccharide (LPS) stimulation via nuclear factor-κB (NF-κB)-phosphodiesterase 4D (PDE4D)-cAMP signaling pathways. Clamping [Cl-]i at high levels or prolonged treatment with LPS augmented serum- and glucocorticoid-inducible protein kinase 1 (SGK1) phosphorylation and subsequently triggered NF-κB activation in airway epithelial cells, whereas inhibition of SGK1 abrogated airway inflammation in vitro and in vivo. Furthermore, Cl--SGK1 signaling pathway was pronouncedly activated in patients with bronchiectasis, a chronic airway inflammatory disease. Conversely, hydrogen sulfide (H2S), a sulfhydryl-containing gasotransmitter, confers anti-inflammatory effects through decreasing [Cl-]i via activation of cystic fibrosis transmembrane conductance regulator (CFTR). Our study confirms that intracellular Cl- is a crucial mediator of sustained airway inflammation. Medications that abrogate excessively increased intracellular Cl- may offer novel targets for the management of airway inflammatory diseases.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29545647 DOI: 10.1038/s41385-018-0013-8
Source DB: PubMed Journal: Mucosal Immunol ISSN: 1933-0219 Impact factor: 7.313